We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Radient Pharmaceuticals Files International Patents in Australia and New Zealand

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Radient Pharmaceuticals Files International Patents in Australia and New Zealand"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Radient Pharmaceuticals Corporation, has announced it has filed for patent protection for its proprietary Onko-Sure® cancer test in Australia and New Zealand.

"Building an intellectual property position in foreign markets protects and supports sales of our proprietary Onko-Sure® cancer test globally. Both Australia and New Zealand have highly developed healthcare markets where we believe Onko-Sure® can add value as a minimally invasive, relatively low cost cancer diagnostic," stated Radient Chairman and CEO Douglas MacLellan.

The Onko-Sure® test kit is a 96-well ELISA test kit sold to clinical reference labs. Labs run individual tests prescribed by doctors. Blood samples can be run, in duplicate, for 40 people, on each test kit.

Onko-Sure® is a non-invasive cancer blood test that has been shown, in a large body of published clinical research, to be effective in the detection of 19 different cancers.